Respiri Confirms No Material Impact on Business Operations from US Tariffs on Chinese-Manufactured Medical Devices

MT Newswires Live

Apr 09, 2025

Respiri (ASX:RSH) confirmed that the recent U.S. tariffs on Chinese-manufactured medical devices will have no material impact on its business operations, according to a Wednesday Australian bourse filing.

It said that it has already over two years' worth of inventory for its wheezo device in the US.

While the tariffs may increase supply costs by around $30 per device for other medical devices, the company can absorb the increase internally, with no change to client pricing or margin exposure, or disruption to existing and new Respiri clients, the filing said.

It noted that US Health Secretary Robert F. Kennedy Jr. advocated for scaling artificial intelligence, telehealth, and virtual care technologies through the healthcare system, which it said supports its connected care business model.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2526388885"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2526388885\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2526388885?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-09 13:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2526388885","market":"nz","top_or_hot":-1,"title":"Respiri Confirms No Material Impact on Business Operations from US Tariffs on Chinese-Manufactured Medical Devices","media":"MT Newswires Live","content":"<html><body><p> Respiri (ASX:RSH) confirmed that the recent U.S. tariffs on Chinese-manufactured medical devices will have no material impact on its business operations, according to a Wednesday Australian bourse filing.</p><p>It said that it has already over two years' worth of inventory for its wheezo device in the US.</p><p>While the tariffs may increase supply costs by around $30 per device for other medical devices, the company can absorb the increase internally, with no change to client pricing or margin exposure, or disruption to existing and new Respiri clients, the filing said.</p><p>It noted that US Health Secretary Robert F. Kennedy Jr. advocated for scaling artificial intelligence, telehealth, and virtual care technologies through the healthcare system, which it said supports its connected care business model.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Respiri Confirms No Material Impact on Business Operations from US Tariffs on Chinese-Manufactured Medical Devices</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRespiri Confirms No Material Impact on Business Operations from US Tariffs on Chinese-Manufactured Medical Devices\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-09 13:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Respiri (ASX:RSH) confirmed that the recent U.S. tariffs on Chinese-manufactured medical devices will have no material impact on its business operations, according to a Wednesday Australian bourse filing.</p><p>It said that it has already over two years' worth of inventory for its wheezo device in the US.</p><p>While the tariffs may increase supply costs by around $30 per device for other medical devices, the company can absorb the increase internally, with no change to client pricing or margin exposure, or disruption to existing and new Respiri clients, the filing said.</p><p>It noted that US Health Secretary Robert F. Kennedy Jr. advocated for scaling artificial intelligence, telehealth, and virtual care technologies through the healthcare system, which it said supports its connected care business model.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7503","symbol_name":"科技股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2526388885","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2526388885","pubTimestamp":1744176558,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Respiri  confirmed that the recent U.S. tariffs on Chinese-manufactured medical devices will have no material impact on its business operations, according to a Wednesday Australian bourse filing.It said that it has already over two years' worth of inventory for its wheezo device in the US.While the tariffs may increase supply costs by around $30 per device for other medical devices, the company can absorb the increase internally, with no change to client pricing or margin exposure, or disruption to existing and new Respiri clients, the filing said.It noted that US Health Secretary Robert F. Kennedy Jr. advocated for scaling artificial intelligence, telehealth, and virtual care technologies through the healthcare system, which it said supports its connected care business model.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7503":"科技股","BK7508":"医药生物股","BK7007":"医疗保健设备"},"translate_title":"Respiri确认美国对中国制造的医疗器械征收关税不会对业务运营产生重大影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RSH.AU":0.9},"content_text":"Respiri (ASX:RSH) confirmed that the recent U.S. tariffs on Chinese-manufactured medical devices will have no material impact on its business operations, according to a Wednesday Australian bourse filing.It said that it has already over two years' worth of inventory for its wheezo device in the US.While the tariffs may increase supply costs by around $30 per device for other medical devices, the company can absorb the increase internally, with no change to client pricing or margin exposure, or disruption to existing and new Respiri clients, the filing said.It noted that US Health Secretary Robert F. Kennedy Jr. advocated for scaling artificial intelligence, telehealth, and virtual care technologies through the healthcare system, which it said supports its connected care business model.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}